SoftOx Solutions AS — Interim / Quarterly Report 2025

Sep 17, 2025

SoftOx Solutions Group Q2 and Half Year Report H1 2025

SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective panantimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.

The SoftOx Solutions Group (SoftOx) comprises the holding company SoftOx Solutions AS and the subsidiaries Water Innovation AB and SoftOx Defense Solutions AS. SoftOx Solutions Group is based in Oslo, Norway, with a subsidiary in Malmö, Sweden, and Clinical Operations in Copenhagen, Denmark.

Highlights for the first half of 2025

FINANCIAL RESTRUCTURING

The financial restructuring described in the 2025 first quarter report has been concluded. Since the extraordinary general assembly in September 2024, the new board and leadership team have been actively engaged in restructuring and refocusing efforts initiated by the previous board. SoftOx's shareholders have supported this process, both through their financial contribution in August 2024 and March 2025 and their confidence in the new leadership.

Following this transition, operations have been strategically narrowed to focus on inhalation-therapeutics opportunities, both as a medical countermeasure application as well as preparing for a therapeutic clinical program focused on lung infections, in general, representing a significant unmet clinical need globally.

REFINED CLINICAL FOCUS

On Sept 2nd , SoftOx announced a shift in its initial clinical focus towards chronic lung diseases in the upcoming proof-of-concept (POC) trial. It will evaluate the safety of SoftOx Inhalation Solution (SIS) across escalating doses and its effects on pulmonary bacterial load, thereby establishing a foundation for additional clinical advancements. The change will not negatively impact previously announced budgets and timelines. Expected readouts from dose escalation in HI 2026, and POC study concluded in QI 2027.

Before the announcement, the board and leadership, assisted by external experts, had carefully evaluated the strategic options for advancing SoftOx's inhaled pharmaceutical platform and implemented an adaptation of the initial clinical focus by initiating its first POC study in chronic lung disease, focusing on people with cystic fibrosis (pwCF), rather than ventilator-associated pneumonia (VAP). The chronic lung disease indication offers a tangible and feasible development path, and positive outcomes will demonstrate the ability of SoftOx's technology to broadly eradicate bacteria in lung infections. Such results will represent a major value inflection point and be a solid foundation for broader clinical development, either by SoftOx or in partnership, including additional chronic indications such as non-cystic fibrosis bronchiectasis (NCFB), as well as acute indications such as VAP. The chronic CF and NCFB indications are characterized by strong commercial potential due to significant addressable markets and likely favorable pricing and reimbursement modalities.

Furthermore, SoftOx Solutions AS has continued its work on inhaled medical countermeasures against biological warfare agents. This initiative has progressed successfully under a collaborative agreement with the European Defence Fund (EDF) and the Norwegian Ministry of Defence (NMOD). It remains on track to deliver the Clinical Trial Application (CTA) for the Phase 1 clinical trial.

As previously reported, SoftOx's technology in the wound and skin areas was spun off to SoftOx's shareholders in early February 2025, and since then, the two companies have operated independently.

Significant efforts have recently been dedicated to cost reduction and resolving past commitments. With many of these challenges now addressed and solved, the primary focus is devoted to planning, prioritizing, and initiating the forthcoming clinical trials as well as securing the financial resources to execute clinical development plans, which can demonstrate the clinical usability of the company's inhaled therapeutics technology and thereby unlock its significant value.

Q2 and HALF YEAR REPORT 2025 FUNDING ACTIVITIES

Private Placement

To strengthen the Company's position ahead of upcoming investor discussions and ensure progress remains on schedule, the board approved a private placement of shares to a selected group of dedicated investors in March 2025. The group included both existing shareholders and international entities newly engaged with SoftOx Solutions AS. The Share Issue generated approximately NOK 9 million in gross proceeds, providing the Company extension of its financial runway and ensuring continued progress of the clinical development plans.

Commited Financing Facility

In August 2025, SoftOx Solutions AS entered into a financing facility with Long State Investments Limited for up to NOK 50 million over 24 months, with the option to extend to NOK 80 million over 36 months. The agreement provides an equity line of credit, giving SoftOx flexibility to issue shares and draw funds at its own discretion, depending on market conditions. The facility offers significant financial flexibility to support ongoing priorities, in particular planned clinical trials, while maintaining control over timing and pricing of placements. As compensation, Long State will receive up to 30 million shares as an implementation fee, a market-based cash consideration, and warrants for up to 60 million shares, subject to approval at an extraordinary general meeting. The Company is not obliged to utilize the facility, and it does not restrict SoftOx from pursuing other financing alternatives. The facility strengthens SoftOx's financial platform, ensures access to capital when needed, and can be terminated by SoftOx at any time without penalty.

Key figures for the SoftOx Solutions Group as of 30.06.2025

Financial figures for the SoftOx Solutions Group are not audited (figures in brackets are comparable figures for 2024).

SoftOx Solutions Group	Second quarter		First Half Year		Year
NOK 1,000	2025	2024	2025	2024	2025	2024
Total operating revenue	4 291	3 062	7 507	4 877	7 507	7 914
Total operating expenses	7 573	8 703	9 503	19 ୧୧୫	9 503	40 377
Operating result	-3 282	-5 640	-1 996	-14 792	-1 996	-32 463
Profit before tax	-3 343	-7 638	-1 390	-28 983	-1 390	-50 459
Net proceeds from equity issues	2 925	0	9 055	0	9 055	35 745
Net change in cash and cash equivalents	-3 043	424	9 260	424	9 260	2 861
Cash and cash equivalents at end of period	19 773	8 075	19 773	8 075	19 773	10 513
Outstanding shares, beginning of the period			1 951 253 942 10 727 871 1 951 253 942	10 727 871	1 951 253 942	10 727 871
Outstanding shares, end of the period			2 240 416 994 516 769 641 2 240 416 994 516 769 641		2 240 416 994	1 951 253 942

The Q2 2025 pre-tax results ended with a loss of NOK 3,3 million (a loss of NOK 7,6 million). The first half of 2025 ended with a loss of NOK 1,4 million (a loss of NOK 29 million).

Clinical Development Strategy

Narrow focus on therapeutics against Respiratory Tract Infections

SoftOx Solutions AS is fully dedicated to developing a completely new class of inhaled antimicrobial pharmaceuticals, effective against bacterial, viral, and fungal infections, which can be deployed into clinical practice without inducing new antimicrobial resistance. This new type of antimicrobial is developed to act locally in the airways, without systemic exposure, and is intended for treatment and potentially prevention of infections in the respiratory tract. It also holds promise to be a long-awaited new tool to be applied towards chronic infections, as well as multi-resistant infections and biological warfare threats. At dose levels tested in a previous trial in healthy volunteers, it is non-toxic and safe in humans, and a proof-ofconcept (PoC) clinical trial in the first indication is planned to start Q1 2026 with submission of the CTA end of Q3 2025.

The corporate focus will remain to advance projects from the concept stage, through clinical development, with the aim, leveraged by compelling pre-clinical and clinical data, to seek strong partnerships for laterstage development and global commercialization. This model has proven effective globally for small innovative companies in the human therapeutics industry.

Lung Infection Applications

STRATEGY

The pharmaceutical product under development at SoftOx Solutions, termed SIS (SoftOx Inhalation Solution), has demonstrated safety in healthy volunteers in a completed Phase 1 trial at the dose levels tested. Toxicology data indicate that higher doses than those tested are feasible. To guide the clinical program, SoftOx's operations team, together with external experts, has developed a strategy that combines dose escalation with a robust proof-of-concept (PoC) approach.

Accordingly, a new clinical trial has been designed to evaluate higher dose levels of SIS in healthy volunteers, alongside a PoC study in patients to assess the reduction in lung bacterial load. The planning process considered key factors such as the ability to collect reliable airway samples, clinical setting, patient availability and eligibility, budget, timeline, and data ownership. Based on this assessment, SoftOx has chosen to refine the focus and proceed with a PoC trial in patients with chronic lung infections, specifically cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (NCFB).

These patient groups, though affected by different diseases, form a relatively homogeneous population. They frequently attend hospitals for treatment, can provide the biological material needed for bacterial load assessment, face a clear unmet medical need, and are experienced in communicating both treatment

effects and potential adverse events. This PoC study may pave the way for subsequent phase 2 and 3 trials across one or more indications, depending on the therapeutic priorities of future partners.

ABOUT THE Proof of Concept (PoC) TRIAL

The trial is designed in two stages: first to evaluate the safety of SIS in healthy volunteers at higher dose levels than previously tested, and then to demonstrate proof-of-concept by measuring reductions in lung bacterial load among patients with chronic airway infections. The study will be set up at the same site as SoftOx's Phase I study, ensuring that the previously communicated timelines and budgets will not be affected.

The clinical trial application (CTA) will be submitted at the end of September 2025, and study initiation is planned for Q1 2026 with a 12-month duration.

HIGHLIGHTS RESEARCH & PRODUCT DEVELOPMENT

• The SoftOx research team, led by CEO Professor Thomas Bjarnsholt, has shown broad antimicrobial efficacy of SIS in vitro. Also, in animal models, reproducible dose-dependent virucidal and bacterial effects of inhaled SIS have been shown in mouse pneumonia models of Influenza A and Pseudomonas aeruginosa, respectively. In addition, the team has shown that the administration of SIS can prevent the spread of Sendai/Parainfluenza virus among co-housed mice. This makes SIS a very promising candidate to prevent and treat airway infections. The team continues to investigate the effects of SIS in animal models.
• The recent thorough investigation to identify the most valuable and broadly applicable initial PoC (Phase 2a) trial has redirected focus from VAP to chronic lung infections, initially cystic fibrosis (CF) and Non-CF bronchiectasis (NCFB).

OUTLOOK

• The Company's first Clinical Trial application (CTA) is on target and will be submitted to authorities end of Q3 2025.
• The first healthy volunteer is expected to be enrolled in the dose escalation part of the study in Q1 2026, and the PoC study will follow seamlessly thereafter, with the trial ending in Q1 2027.
• For the trial, a new Drug Substance has been developed through a CMO, and a verification batch has been successfully produced.
• Technical batches of the drug product have been successfully produced.

Medical Countermeasure Applications

STRATEGY

SoftOx Defense Solutions AS (SDS) develops inhaled pharmaceuticals to be deployed as countermeasures against biological warfare threats through a contract with the European Defence Fund (EDF), together with the Norwegian Defence Research Establishment (FFI) and several other European partners. The project started in December 2022 and runs until November 2026. The activity in SDS is financed by the European Defence Fund (EDF) and the Norwegian Ministry of Defence (NMOD) and has not been affected by the previous financial challenges in SoftOx Solutions AS. Commercial rights are retained by the SoftOx group.

HIGHLIGHTS RESEARCH & PRODUCT DEVELOPMENT

• Several partners are conducting in vivo testing of SIS's efficacy in several animal infection/lung models. Preliminary results show good efficacy in a murine P. aeruginosa pneumonia model as well as in a murine influenza model.
• A nebulization device for the upcoming phase 1 trial has been selected.
• A second-generation SIS has been developed under the EDF project.
• The testing of the second-generation SIS by several partners has shown great efficacy against a variety of relevant respiratory pathogens, including severe pathogens/biological weapons like Bacillus anthracis.
• For the Phase 1 trial, a new Drug Substance has been developed through a CMO, and a verification batch has been successfully produced.
• Technical batches of the drug product have been successfully produced.

OUTLOOK

• The work on developing SIS as a Medical Countermeasure against biological warfare agents is progressing according to the project plans.
• A pre-submission meeting was held with the Irish health authorities, HPRA, and a CTA for the planned phase 1 trial is on target to be submitted in H2 2025.
• In the clinical Phase 1 trial, the concentrations of SIS will be increased to achieve a larger therapeutic window.
• The Phase 1 study will be initiated in Q1 2026.

Financial matters

Financial figures for the SoftOx Solutions Group are not audited (figures in brackets are comparable figures for 2024).

Profit and Loss Statement

During the first half of 2025, the company recognized NOK 7,5 million (NOK 4,9 million) as income in connection with funding from the European Defence Fund and Norwegian Research Fund.

In the first half of 2025, salary costs were NOK 3,2 million (NOK 2,5 million). NOK 3,1 million is related to the EDF/Counteract project.

Other operating costs of the first half year 2025 are NOK 4,7 million (NOK 14,3 million). NOK 4,2 is related to the EDF/Counteract project.

Total operating expenses of the first half year 2025 are NOK 9,5 million (NOK 19,7 million). NOK 7,3 is related to the EDF/Counteract project.

Net Financial items for the first half year 2025 are NOK 0,6 million (NOK 14,2 million).

Pre-tax results ended with a loss of NOK 1,4 million (loss of NOK 29 million) for the first half of 2025. Results are impacted by the execution of the restructuring efforts.

Cash flow and consolidated balance sheet

Of the capitalized assets, the company has activated its IP and patent costs worth NOK 14 million (NOK 11 million). The IP/Patent costs are depreciated over 5 years. Deferred tax assets will not be addressed here, as the tax calculations will be performed for the end-of-the-year reporting, based on audited figures.

The Company's cash position has been strengthened following the successful completion of the Private Placement, as announced in the stock notice on March 25, 2025. The proceeds provide liquidity to support ongoing operations and strategic initiatives, including preparations for the forthcoming proof-of-concept clinical trial and the EDF/Counteract project. In August 2025, the Company entered into a flexible financing facility with Long State Investments Limited of up to NOK 50 million over 24 months (with an extension option to NOK 80 million over 36 months), providing the Company with access to capital as needed to support operations and growth. The company is not obliged to utilize the facility and is not restricted from pursuing other financing alternatives. On the 11th of September 2025, the Company resolved to request the issuance of up to 60 million shares under the financing facility. Upon completion of the 10-day prising period, the relevant number of the Company's shares will be issued to Long State at the relevant price. In addition, the Company will continuously consider other funding sources if they become available to secure the approximately EUR 8 million needed to fund clinical activities, which can demonstrate the clinical utility of SIS and enable productive partnership discussions by 2027. Additionally, efforts to optimize cost structures and streamline operations have improved financial resilience, ensuring efficient capital allocation in alignment with the Company's long-term objectives.

Legal Matters

Reference is made to the stock notice dated 27 February 2025, where the Company has settled the legal dispute between the Company and a former consultant claiming to have a bonus claim for services rendered in 2022. The Company has settled MNOK 1,5 ex VAT for immediate payment and MNOK 0,8 ex VAT for payment within 30.06.2026.

The Company has also settled an issue related to immaterial rights related to the further development of certain aspects of SoftOx's technology, by issuing 16,5 million shares in the company to its counterpart.

Other than a dispute with a former employee that has been settled, and the two cases mentioned above, the Company is not, nor has it been, during the preceding 12 months involved in any legal, governmental, or arbitration proceedings which may have, or have had in the recent past, significant effects on the Company's and/or the Group's financial position or profitability, and the Company is not aware of any such proceedings which are pending or threatened.

Patent Strategy

The Company pursues an active patent strategy, including improvements as well as pruning of the existing portfolio and filing of new patent applications to further protect the SoftOx technology platform. The company takes advice from a qualified external IP/Patent advisory team.

Option/Warrant Programme

According to the General Assembly on 27th of June 2025, the Company has issued 196 036 487 stand-alone subscription rights/warrants to employees and board members, as outlined in the list below.

		Total allocation
Name	Title	% of total issued equity	Number of warrants	Upfront Grant (%) of total	Upfront Grant # (Strike 0,052 (*))	Vesting options (Strike 0,079)	Vesting (years)	Annual vesting #	Accel. Vesting
Medical Consulting Aps (Thomas Bjarnsholt) CEO		1.00 %	22 404 170	25 %	5601042	16 803 127	3	5601042	ves
Bonica AS (Ingrid Juven)	CFO	1.00 %	22 404 170	25 %	5601042	16 803 127	3	5 601 042	ves
Ulrik Spork	СВО	3,00 %	67 212 510	33 %	22 180 128	45 032 382	3	15 010 794	ves
Christian V Thomsen	VCBO	1,50 %	33 606 255	25 %	8 401 564	25 204 691	3	8 401 564	ves
Andrian Bignami	Board member	0,50 %	11 202 085	25 %	2 800 521	8 401 564	3	2 800 521	ves
TBD]	Board member	0,50 %	11 202 085	0 %		11 202 085	3	3 734 028	ves
ESOP (allocated by BoD)	Key employees	1,25 %	28 005 212	0%		28 005 212	3	9 335 071	yes
		8.75 %	196 036 487		44 584 298	151 452 189		50 484 063
* Average 10 days VWAP 12.09.24 and 12.06.25
** 10 days VWAP 12.06.2025

According to the General Assembly on 28th June 2024, the Company has issued 30 006 250 stand-alone subscription rights/warrants to employees and board members, as outlined in the list below.

KEY PERSONELL & BOARD		Amount	Warrents	Duration	Strike
Hermod Farms (*)	Geir Almãs	Key Personell	1 944 000	9 720 000 5 years		0,4
Harstad Experience (*)	Christian Harstad	Key Personell	1 194 750	5 973 750 5 years		0.4
Medical Consulting	Thomas Bjarnsholdt	Key Personell	895 000	4 475 000 5 years		0.4
Bonica	Ingrid Juven	Key Personell	1 080 000	5 400 000 5 years		0,4
Elin Jørgensen		Key Personell	171 875	859 375	5 years	0,4
Henrik Nielsen (*)		Board	171 875	859 375	5 years	0.4
Olav Jarlsby (*)		Board	171 875	859 375	5 years	0.4
Adrian Bignami		Board	171 875	859 375	5 years	0,4
Jørgen Berggrav (*)		Board	200 000	1 000 000 5 years		0,4
SUM			6 001 250	30 006 250

Significant risk factors for the company

• ➢ Clinical research studies always involve an inherent risk of being delayed and not delivering results as expected.
• ➢ Financial risks mainly consist of currency, credit, and liquidity risk. The company depends on funding it's R&D activities with funds from investors.
• ➢ Intellectual property risks. SoftOx works closely with external patent counsels to minimize the risk of patent infringement claims and prepare any patent defence if necessary.

Declaration by the Board

We confirm, to the best of our knowledge, that the unaudited, summarised half year report 2025 accounts for the period 1st of January to 30 th of June 2025 have been prepared following accounting standards for the group and that the information contained in these accounts gives a true and fair view of the group's assets, liabilities, financial position and profits as a whole, and that the report provides a true and fair view of the information specified in Section 5-6, fourth paragraph, of the Norwegian Securities Trading Act.

Oslo, 16th of September 2025

SIGNED

Ulrik Spork, Chairman of the Board

_________________________

_________________________

SIGNED

Christian Vinding Thomsen, Board Member

SIGNED

Adrian Bignami, Board Member

_______________________

SIGNED

_______________________ Tore Duvold, Board Member

_______________________

SIGNED

Ingrid Juven, Managing Director/CFO

Q2 and HALF YEAR REPORT 2025 Profit and Loss Statement

SoftOx Solutions Group	Second quarter			First Half Year		Year
NOK 1,000	2024	2024	2025	2024	2025	2024
Other operating revenues	4 291	3 062	7 507	4877	7 507	7 914
Total operating revenues	4 291	3 062	7 507	4 877	7 507	7 914
Personnel expenses	1 838	1 411	3 241	2 463	3 241	4 985
Other operating expenses	4 955	6 153	4 704	14 284	4 704	30 020
Depreciation	779	1 138	1 558	2 922	1 558	5372
Depreciation, goodwill	0		0	0	0	0
Total operating expenses	7 573	8 703	9 503	19 669	9 503	40 377
Operating result	-3 282	5 640	-1 996	-14 792	-1 996	-32 463
Net financial items	-62	1 997	606	-14 191	606	-17 996
Profit before tax	-3 343	7 638	-1 390	-28 983	-1 390	-50 459
ax	0		0	0	0	7 515
Annual profit/loss	-3 343 -	7 638	-1 390	-28 983	-1 390	-42 944

Q2 and HALF YEAR REPORT 2025 Balance sheet 30.06.25

Statement of financial position	30.06.2025	30.06.2024	31.12.2024
SoftOx Solutions Group
NOK 1,000
Other intangible assets	14 039	11 121	26 412
Deferred tax asset	84 203	76 688	84 203
Goodwill from acquisition of subsidiary	0	0	0
Total intangible assets	98 242	87 809	110 615
Production equipment	0	17	0
Total fixed assets	0	17	0
Non-current assets	98 242	87 826	110 615
Inventory	0	0	0
Total inventory	0	0	0
Other receivables	0	945	13
Total receivables	0	ਰੇ45	13
Cash and cash equivalents	19 773	8 075	10 513
Deposits	0		0
Current assets	19 773	9 020	10 526
Total assets	118 015	96 847	121 141

Total equity and liabilities	118 015	96 847	121 141
Total liabiities	13 714	22 276	25 956
Total current liabilities	13 714	22 276	25 956
Accounts payable	3 488	9 878	6 382
Other current liabilities	10 386	12 778	10 143
Shareholder loans	0	0	O
Public duties payable	-160	-380	-269
Dividend	0		10 000
Other non-current liabilities	0	0	O
Other long term debts	0	0	0
Total equity	104 301	74 571	95 185
Other equity	-3 745	41 839	3 242
Total paid up capital	108 046	32 732	91 942
Share premium reserve	63 238	22 396	52 917
Share capital	44 808	10 335	39 025

Q2 and HALF YEAR REPORT 2025 Cash Flow Statement

Cash flow statement	Second quarter		First Half Year		Year
	2024	2024	2025	2024	2025	2024
SoftOx Solutions Group
NOK 1.000
Cash flow from operating activities
Net result before taxes	-3 343	-7 638	-1 390	-28 983	-1 390	-50 459
Tax paid	0	0	0	0	0
Depreciation	779	1 138	1 558	2 922	1 558	5 372
Change in current assets	0	11	13	4	13	ਰੇਤੇ ਦ
Change in current liabilities	-4 423	-47 844	-12 242	-27 007	-12 242	-23 327
Convertion of debts/dividend	609	90 214	1 066		1 066	100 039
Net cash flow from operating activities	-6 379	-49 333	-10 995	-53 064	-10 995	32 561
Cash flow from investment activities
Investments in non-current assets	0	-758	10 815	-2 112	10815	-19 835
Net cash flow from investment activities	0	-758	10 815	-2 112	10 815	-19 835
Cash flow from financing activities
Proceeds from equity issues	2 925	10 994	9 055	10 994	9 055	35 745
Other financing activities	410	-46 067	410	-45 589	410	-45 589
Translation differences	0	-22	-23	-19	-23	-19
Net cash flow from financing activities	3 335	-35 095	9 442	-34 613	9 442	-9 863
Net change in cash and cash equivalents	-3 043	424	9 260	-89 790	9 260	2 861
Cash and cash equivalents at begining of period	22 816	7 652	10 513	7 652	10 513	7 652
Cash and cash equivalents at end of period	19 773	8 075	19 773	8 075	19 773	10 513

Statement of changes in equity (*)

Statement of changes in equity
SoftOx Solutions Group
		Second quarter		First Half Year		Year
NOK 1,000	2025	2024	2025	2024	2025	2024
Equity at end of prior period	103 700	-18 976	95 185	2 366	95 185	2 366
Share issues	3 991	101 208	10 531	101 208	10 531	135 783
Loss for the period	-3 343	-7 638	-1 390	-28 983	-1 390	-42 944
Other changes in equity	-25	-24	-25	-21	-25	-21
Equity at end of period	104 324	74 571	104 301	74 571	104 301	95 185

(*) The first half of 2024 and 2025 is before tax, and the Year 2024 is after tax. The full year 2024 is after tax, and the full year 2025 is before tax.

General Accounting Principles

The financial statements have been prepared in accordance with the Norwegian Accounting Act and generally accepted accounting principles in small companies in Norway.

Basis for consolidation

The Group's consolidated financial statements comprise SoftOx Solutions AS and companies in which SoftOx Solutions AS has a controlling interest. A controlling interest is normally obtained when the Group owns more than 50% of the shares in the company and can exercise control over the company. Minority interests are included in the Group's equity. Transactions between group companies have been eliminated in the consolidated financial statement. The consolidated financial statement has been prepared in accordance with the same accounting principles for both the parent and subsidiary.

The purchase method is applied when accounting for business combinations. Companies that have been bought or sold during the year are included in the consolidated financial statements from the date when control is achieved and until the date when control ceases.

An associate is an entity in which the Group has a significant influence but does not exercise control the management of its finances and operations (normally when the Group owns 20-50% of the company). The consolidated financial statements include the Group's share of the profits/losses from associates, accounted for using the equity method, from the date when a significant influence is achieved and until the date when such influence ceases.

When the Group's share of a loss exceeds the Group's investment in an associate, the amount carried in the Group's balance sheet is reduced to zero, and further losses are not recognized unless the Group has an obligation to cover any such loss.

Use of estimates

The management has used estimates and assumptions that have affected assets, liabilities, incomes, expenses, and information on potential liabilities in accordance with generally accepted accounting principles in Norway.

Foreign currency translation

Transactions in foreign currency are translated at the rate applicable on the transaction date. Monetary items in a foreign currency are translated into NOK using the exchange rate applicable on the balance sheet date. Non-monetary items that are measured at their historical price expressed in a foreign currency are translated into NOK using the exchange rate applicable on the transaction date. Non-monetary items that are measured at their fair value expressed in a foreign currency are translated at the exchange rate applicable on the balance sheet date. Changes to exchange rates are recognized in the income statement as they occur during the accounting period.

Revenue recognition

Revenues from the sale of goods are recognized in the income statement once delivery has taken place and most of the risk and return has been transferred. Revenues from the sale of services are recognized in the income statement according to the project's level of completion, provided the outcome of the transaction can be estimated reliably. Progress is measured as the number of hours spent compared to the total number of hours estimated. When the outcome of the transaction cannot be estimated reliably, only revenues equal to the project costs that have been incurred will be recognized as revenue. The total estimated loss on a contract will be recognized in the income statement during the period when it is identified that a project will generate a loss.

Income tax

The tax expense consists of the tax payable and changes to deferred tax. Deferred tax/tax assets are calculated on all differences between the book value and tax value of assets and liabilities. Deferred tax is calculated as the tax rate of temporary differences and the tax effect of tax losses carried forward. Deferred tax assets are recorded in the balance sheet when it is more likely than not that the tax assets will be utilized. Taxes payable and deferred taxes are yearly recognized directly in equity to the extent that they relate to equity transactions.

Balance sheet classification

Current assets and short-term liabilities consist of receivables and payables due within one year, and items related to the inventory cycle. Other balance sheet items are classified as fixed assets / long term liabilities. Current assets are valued at the lower of cost and fair value. Short-term liabilities are recognized at nominal value. Fixed assets are valued at cost, less depreciation and impairment losses. Long-term liabilities are recognized at nominal value.

Research and development

Development costs are capitalized providing that a future economic benefit associated with development of the intangible asset can be established and costs can be measured reliably. Otherwise, the costs are expensed as incurred. Capitalized development costs are amortized linearly over their useful life. Research costs are expensed as incurred.

Plant and equipment

Plant and equipment are capitalized and depreciated linearly over the estimated useful life. Significant fixed assets which consist of substantial components with dissimilar economic life have been unbundled; depreciation of each component is based on the economic life of the component. Costs for maintenance are expensed as incurred, whereas costs for improving and upgrading property plant and equipment are added to the acquisition cost and depreciated with the related asset. If the carrying value of a non-current asset exceeds the estimated recoverable amount, the asset is written down to the recoverable amount. The recoverable amount is the greater of the net realisable value and value in use. In assessing value in use, the discounted estimated future cash flows from the asset are discounted.

Subsidiaries

Subsidiaries are valued at cost in the company accounts. The investment is valued as the cost of the shares in the subsidiary, less any impairment losses. An impairment loss is recognized if the impairment is not considered temporary, in accordance with generally accepted accounting principles. Impairment losses are reversed if the reason for the impairment loss disappears in a later period.

Inventories

Inventories are recognized at the lowest of cost and net selling price. The net selling price is the estimated selling price in the case of ordinary operations minus the estimated completion, marketing and distribution costs. The cost is arrived at using the FIFO method and includes the costs incurred in acquiring the goods and the costs of bringing the goods to their current state and location.

Accounts receivable and other receivables

Accounts receivable and other current receivables are recorded in the balance sheet at nominal value less provisions for doubtful accounts. Provisions for doubtful accounts are based on an individual assessment of the different receivables. For the remaining receivables, a general provision is estimated based on expected loss.

Pensions

Under the defined contribution scheme, the Group does not commit itself to paying specific future benefits but makes annual contributions to the employees' pension savings. The Group's payment to the defined contribution scheme amounts to 7% of salary for Norwegian employees.

Cash flow statement

The cash flow statement is presented using an indirect method. Cash and cash equivalents include cash, bank deposits, and other short-term, highly liquid investments with maturities of three months or less.

Glossary

CBRN	Chemical, Biological, Radiological, and Nuclear
EDF	European Defence Fund
EN	European Norm
EU	European Union
FDA	U.S. Food and Drug Administration
IP	Intellectual property
KemI	Swedish Chemicals Agency
MRSA	Methicillin-resistant Staphylococcus aureus
OTA	Other Transaction Agreement
R&D	Research and Development
SBE	SoftOx Biofilm Eradicator (SoftOx Infection Remover)
SDS	SoftOx Defense Solutions AS
Shares	SoftOx Solutions issued and outstanding shares, unless the context indicates otherwise,
	including the Offer Shares offered in the Offering.
SIS	SoftOx Inhalation Solution
SWIS	SoftOx Wound Irrigation Solution

Contact us

SoftOx Solutions AS

Bærum

Norway

https://soft-ox.com/